AstraZeneca Plc will pay Dizal Jiangsu Pharmaceutical Co. $600 million upfront for global rights to a lung cancer drug in a deal valued at $1.5 billion, according to Bloomberg.
The agreement adds a commercial-ready treatment to AstraZeneca’s lung cancer franchise amid a wave of drug-licensing deals involving Chinese companies.
AstraZeneca to Pay Dizal Jiangsu $600 Million Upfront in $1.5 Billion Lung Cancer Drug Deal
2026-07-14 07:12:32
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
83% Of Investors Expect No Fed Rate Hike Before November U.S. Midterm Elections, Survey ShowsNext article：
英国招聘企业业绩改善，劳动力市场现企稳迹象
